• Alternariol-Induced Hepatic Stellate Transdifferentiation in

  2026-06-23

  This study elucidates how Alternariol (AOH) and related Alternaria toxins drive hepatic stellate cell LX-2 transdifferentiation, implicating them in liver fibrosis through activation of key molecular pathways. By leveraging lncRNA-mRNA omics and pathway analysis, the research advances mechanistic understanding and introduces a laccase-based detoxification strategy.

• SNS-032 (BMS-387032): CDK2/7/9 Inhibitor in Cancer and Antiv

  2026-06-23

  SNS-032 (BMS-387032) is a potent, selective cyclin-dependent kinase inhibitor targeting CDK2, CDK7, and CDK9, with validated applications in cancer and emerging roles in host-targeted antiviral strategies. Its molecular and cellular effects are well-documented, making it a valuable tool for research in cell cycle regulation and transcriptional control.

• Oteseconazole (VT-1161): Precision Tools for Candida Researc

  2026-06-22

  Oteseconazole (VT-1161) stands out as a selective tetrazole inhibitor for dissecting Candida resistance and advancing recurrent vulvovaginal candidiasis models. This guide delivers actionable protocols, troubleshooting strategies, and comparative insights to empower translational antifungal research.

• Potassium Iodide in Precision Immunotherapy: Protocols & Fut

  2026-06-22

  Discover how Potassium Iodide (KI) enables advanced thyroid protection and precision assay development in immunotherapy research. This article uniquely explores KI’s translational impact, practical protocol optimization, and the latest insights from responsive drug delivery innovations.

• Oteseconazole (VT-1161): Precision Antifungal Strategies for

  2026-06-21

  Explore the scientific underpinnings of Oteseconazole (VT-1161) as a next-generation antifungal agent for Candida infections, with special focus on resistance, selectivity, and research protocols. This article uniquely dissects molecular innovations and their impact on experimental design.

• Human SAN-Cardiac Plexus Assembloids Model Pacemaker Maturat

  2026-06-20

  This study introduces a human pluripotent stem cell-derived assembloid system integrating sinoatrial node (SAN) and cardiac plexus organoids, enabling precise modeling of neuro-cardiac interactions driving pacemaker maturation. The platform reveals neuron-to-pacemaker signaling pathways critical for SAN development, with significant implications for translational cardiac research.

• Cyclosporin A: Mechanistic Precision for Translational Immun

  2026-06-19

  This thought-leadership article unites mechanistic insight on Cyclosporin A with actionable strategies for translational researchers. Focusing on the unique inhibition of cyclophilins and calcineurin-NFAT signaling, it explores Cyclosporin A’s validated utility in autoimmune disorder research, apoptosis modulation, and cross-domain models such as viral entry and retinal ischemic injury. The article provides protocol guidance, critically discusses competitive benchmarks, and outlines the evolving translational landscape, positioning APExBIO’s Cyclosporin A as a pivotal tool for precision research.

• Carvedilol Phosphate in Hepatic IRI: Protocols & Innovations

  2026-06-19

  Carvedilol Phosphate stands out as a non-selective beta blocker with unique solubility and purity, making it a powerful tool for modeling hepatic ischemia–reperfusion injury (IRI) and dissecting GPCR-mediated macrophage responses. Recent mechanistic advances, including the Arrb2-driven M2 polarization pathway, set the stage for next-generation pharmacological research workflows.

• Tofacitinib (CP-690550): Empowering Immune Cell Assay Innova

  2026-06-18

  Tofacitinib (CP-690550) uniquely enables researchers to dissect cytokine signaling and mitochondrial repair in immune modulation workflows. This article translates the latest mechanistic breakthroughs into actionable protocols and troubleshooting guidance, ensuring robust results for advanced immunometabolic research.

• Gene Expression Profiling Predicts Olaparib Response in MPM

  2026-06-18

  Borchert et al. (2019) identify homologous recombination repair (HRR) pathway defects, notably the BRCAness phenotype and BAP1 mutations, as markers of sensitivity to PARP inhibition in malignant pleural mesothelioma (MPM). Their findings enable more precise stratification of patients for targeted therapy and highlight new opportunities for research into chemotherapy resistance mechanisms.

• Indometacin Sodium: Applied Workflows for Inflammation Assay

  2026-06-17

  Indometacin Sodium Trihydrate enables robust anti-inflammatory, pain, and neuroregenerative research through precise, reproducible workflows. Discover advanced protocol enhancements, troubleshooting tactics, and evidence-based insights that uniquely position this NSAID for both cellular and in vivo models.

• Sitagliptin Phosphate Monohydrate: Expanding Incretin Resear

  2026-06-17

  This article explores the mechanistic and translational impact of Sitagliptin phosphate monohydrate as a DPP-4 inhibitor, contextualizing new findings on GI mechanosensation and glucose regulation. It offers experimental strategy insights for diabetes researchers and positions APExBIO’s product as a best-in-class tool for advanced metabolic studies.

• ERAD-Hijacking Chimeras Enable Targeted Degradation of TM Pr

  2026-06-16

  Song et al. present ERAD-engaging chimeras (ERADECs), a new small-molecule strategy to induce selective degradation of transmembrane proteins via the ER-associated degradation pathway. This innovation overcomes longstanding technical barriers in targeted protein degradation, supporting new directions in membrane protein research and drug discovery.

• Protease Inhibitor Cocktail EDTA-Free: Precision in Protein

  2026-06-16

  The Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) from APExBIO delivers broad-spectrum, phosphorylation-compatible protease inhibition for protein extraction workflows where divalent cation preservation is critical. Discover how this formulation streamlines modern proteomics, supports advanced post-translational analyses, and resolves common pitfalls in cell and tissue lysis.

• Dovitinib (TKI-258): Systems-Level Dissection of RTK Inhibit

  2026-06-15

  Explore how Dovitinib (TKI-258) enables systems-level mapping of RTK-driven signaling and apoptosis induction in cancer cells. This article uniquely integrates quantitative pathway analysis and recent immunomodulatory insights to guide advanced experimental design.

14838 records 1/990 page Next 12345 下5页 Last page